Lunai Bioworks Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Lunai Bioworks Inc. (LNAI) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $96.73 thousand for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-16.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2019-05-16
- Lunai Bioworks Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2019-03-31 was $96.73K.
- Lunai Bioworks Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2018-12-31 was $1.78M.
- Lunai Bioworks Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2018-09-30 was $46.17K, a 97.11% decline year-over-year.
- Lunai Bioworks Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2017-09-30 was $1.60M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month |
|---|---|---|---|
| 2019-03-31 | $96.73K 10-Q · filed 2019-05-16 | $1.88M derived: sum of 2 quarters · filed 2019-05-16 | $1.93M derived: sum of 3 quarters · filed 2019-05-16 |
| 2018-12-31 | $1.78M 10-Q · filed 2019-05-16 | $1.83M derived: sum of 2 quarters · filed 2019-05-16 | |
| 2018-09-30 | $46.17K 10-Q · filed 2019-05-16 | ||
| 2017-09-30 | $1.60M 10-Q · filed 2019-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |